Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of VGX-3100 for HPV-16/18-related cervical HSIL
2016-002761-63Phase 3Unknown
- Sponsor
- Inovio Pharmaceuticals, Inc.
- Start
- Jul 2017
- Modality
- Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in cervical intraepithelial neoplasia (CIN) and human papillomavirus infection comparing VGX-3100 with Placebo (2 arms). Primary endpoint: Combined histopathologic regression and virologic clearance at Week 36. Status: unknown.
02
Drugs
bizalimogene ralaplasmid
03
Conditions
cervical intraepithelial neoplasia (CIN)human papillomavirus infection
Beyond the preview
Go deeper on 2016-002761-63.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002761-63.